跳至主要内容
临床试验/NCT06030219
NCT06030219已完成1 期

Microbiome Effect of Omadacycline on Healthy Volunteers

University of Houston1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2020年10月12日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
32
试验地点
1
主要终点
Microbiome changes

研究概览

简要总结

The goal of this study is to assess microbiome changes associated with omadacycline vs. comparators (moxifloxacin or oral vancomycin). Using a phase I study design, healthy volunteers aged 18-40 years will be given a 10-day course of either omadacycline 450 mg days 1 and 2 followed by 300 mg PO once daily, moxifloxacin 400 mg once daily, or oral vancomycin 125 mg given four times daily. Stool will be collected at baseline, daily during therapy, and at two follow-up time periods (days 13-14 and days 30-32). DNA will be extracted from stool and used for qPCR biomass and microbial metagenomic experiments. Results from the study will provide definitive data on the microbiome effects of omadacycline versus comparator antibiotics.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Omadacycline

Experimental

Subjects will receive 3 tablets on day 1 and day 2 (450 mg) followed by 2 tablets (300 mg) for days 3 through 10.

干预措施: Omadacycline (Drug)

Vancomycin (oral)

Active Comparator

Vancomycin 125 mg capsules will be taken four times daily for a total of 10 days.

干预措施: Vancomycin Pill (Drug)

Moxifloxacin

Active Comparator

Moxifloxacin 400 mg tablets will be taken once per day for a total of 10 days.

干预措施: Moxifloxacin (Drug)

结局指标

主要结局

Microbiome changes

时间窗: During dosing and 30 day follow up period

Metagenomic changes (16S rRNA) and qPCR for individual bacterial species

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kevin W. Garey

Professor and Chair

University of Houston

研究点 (1)

Loading locations...

相似试验